Changes to the Code
S. 2372 · 340B PATIENTS Act of 2025 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 256b Limitation on prices of drugs purchased by covered entities
8 changes the bill asks for here, 6 carried out
- Carried out:
by striking that the manufacturer furnish and inserting the following:(A) the manufacturer furnish that—;
- Carried out:
by striking
ceiling price
), and and insertingceiling price
);; - Not carried out:
by striking shall require that the manufacturer offer and inserting the following:(B) the manufacturer offer; and
The bill puts these words in a provision numbered (B), which can't be the first one in § 256b(a)(1), so we couldn't tell where it goes.
Technical detail
(B) can't be the first provision of /us/usc/t42/s256b/a/1 - Not carried out:
by striking the period at the end and inserting the following:
(C) the manufacturer not place any conditions on the ability of a covered entity to purchase and use a covered outpatient drug at or below the applicable ceiling price, regardless of the manner or location in which the drug is dispensed, if such conditions— (i) would place …
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: striking the period at the end and inserting the following: QCONTENT; and - Carried out:
by adding at the end the following new paragraph:
(11) Contract Pharmacies.— The requirements and prohibitions under paragraph (1) shall apply in the case of a covered entity that elects to contract with one or more pharmacies to dispense, to patients of the covered entity, covered outpatient drugs purchased by the covered …
- Carried out:
in clause (vi), in the matter preceding subclause (I), by inserting
, in the case of a manufacturer overcharging a covered entity for covered outpatient drugs
afterpenalties
; and - Carried out:
by adding at the end the following:
(vii) The imposition of sanctions in the form of civil monetary penalties in the case of a violation of subsection (a)(1)(C) or (a)(11), other than an overcharge, which— (I) shall be assessed according to standards established in regulations to be promulgated by the Secretary …
- Carried out:
in paragraph (3), by adding at the end the following:
(D) Claims of violations.— Not later than 180 days after the date of the enactment of this subparagraph, the Secretary shall promulgate regulations to permit covered entities to assert claims of violations of subsections (a)(1) and (a)(11) under the process established under subparagraph (A)..
§ 256b(a)
§ 256b. Limitation on prices of drugs purchased by covered entities
(a) Requirements for agreement with Secretary
(1) In general [inserted: The Secretary shall enter into an agreement with each manufacturer of covered outpatient drugs under which the amount required to be paid (taking into account any rebate or discount, as provided by the Secretary) to the manufacturer for covered outpatient drugs (other than drugs described in paragraph (3)) purchased by a covered entity on or after the first day of the first month that begins after November 4, 1992, does not exceed an amount equal to the average manufacturer price for the drug under title XIX of the Social Security Act [42 U.S.C. 1396 et seq.] in the preceding calendar quarter, reduced by the rebate percentage described in paragraph (2). Each such agreement shall require that—]
(A) [inserted: the manufacturer furnish the Secretary with reports, on a quarterly basis, of the price for each covered outpatient drug subject to the agreement that, according to the manufacturer, represents the maximum price that covered entities may permissibly be required to pay for the drug (referred to in this section as the “ceiling price”); shall require that the manufacturer offer each covered entity covered outpatient drugs for purchase at or below the applicable ceiling price if such drug is made available to any other purchaser at any price.]
[struck: The Secretary shall enter into an agreement with each manufacturer of covered outpatient drugs under which the amount required to be paid (taking into account any rebate or discount, as provided by the Secretary) to the manufacturer for covered outpatient drugs (other than drugs described in paragraph (3)) purchased by a covered entity on or after the first day of the first month that begins after November 4, 1992, does not exceed an amount equal to the average manufacturer price for the drug under title XIX of the Social Security Act [42 U.S.C. 1396 et seq.] in the preceding calendar quarter, reduced by the rebate percentage described in paragraph (2). Each such agreement shall require that the manufacturer furnish the Secretary with reports, on a quarterly basis, of the price for each covered outpatient drug subject to the agreement that, according to the manufacturer, represents the maximum price that covered entities may permissibly be required to pay for the drug (referred to in this section as the “ceiling price”), and shall require that the manufacturer offer each covered entity covered outpatient drugs for purchase at or below the applicable ceiling price if such drug is made available to any other purchaser at any price.]
(2) “Rebate percentage” defined
(A) In general For a covered outpatient drug purchased in a calendar quarter, the “rebate percentage” is the amount (expressed as a percentage) equal to—
§ 256b(a)–(b)
(a)(2)(A)(i)–(8) unchanged ·
(9) Notice to manufacturers The Secretary shall notify manufacturers of covered outpatient drugs and single State agencies under section 1902(a)(5) of the Social Security Act [42 U.S.C. 1396a(a)(5)] of the identities of covered entities under this paragraph, and of entities that no longer meet the requirements of paragraph (5) or that are no longer certified pursuant to paragraph (7).
(10) No prohibition on larger discount Nothing in this subsection shall prohibit a manufacturer from charging a price for a drug that is lower than the maximum price that may be charged under paragraph (1).
(11) [inserted: Contract Pharmacies.—] [inserted: The requirements and prohibitions under paragraph (1) shall apply in the case of a covered entity that elects to contract with one or more pharmacies to dispense, to patients of the covered entity, covered outpatient drugs purchased by the covered entity at or below the applicable ceiling price described in paragraph (1).]
(b) Other definitions
(1) In general In this section, the terms “average manufacturer price”, “covered outpatient drug”, and “manufacturer” have the meaning given such terms in section 1927(k) of the Social Security Act [42 U.S.C. 1396r–8(k)].
§ 256b(d)Improvements in program integrity(1)–(2)
(b)(2)–(d)(1) unchanged ·
(v) Selective auditing of manufacturers and wholesalers to ensure the integrity of the drug discount program under this section.
(vi) The imposition of sanctions in the form of civil monetary penalties, [inserted: in the case of a manufacturer overcharging a covered entity for covered outpatient drugs, ]which—
(I) shall be assessed according to standards established in regulations to be promulgated by the Secretary not later than 180 days after March 23, 2010;
(II) shall not exceed $5,000 for each instance of overcharging a covered entity that may have occurred; and
(III) shall apply to any manufacturer with an agreement under this section that knowingly and intentionally charges a covered entity a price for purchase of a drug that exceeds the maximum applicable price under subsection (a)(1).
(vii) [inserted: The imposition of sanctions in the form of civil monetary penalties in the case of a violation of subsection (a)(1)(C) or (a)(11), other than an overcharge, which—]
(I) [inserted: shall be assessed according to standards established in regulations to be promulgated by the Secretary not later than 180 days after the date of enactment;]
(II) [inserted: shall apply to any manufacturer with an agreement under this section that intentionally violates a requirement under subsection (a)(1)(C) or (a)(11), other than an overcharge;]
(III) [inserted: shall not exceed $2,000,000 for each day of such violation;]
(IV) [inserted: shall be in an amount determined by the Secretary, taking into account factors such as the nature and extent of the violation and harm resulting from such violation, including, where applicable, the number of drugs affected and the number of covered entities affected; and]
(V) [inserted: shall continue to be imposed each day until such manufacturer is no longer in violation of a requirement under subsection (a)(1)(C) or (a)(11), other than an overcharge.]
(2) Covered entity compliance
(A) In general From amounts appropriated under paragraph (4), the Secretary shall provide for improvements in compliance by covered entities with the requirements of this section in order to prevent diversion and violations of the duplicate discount provision and other requirements specified under subsection (a)(5).
§ 256b(d)–(e)
(d)(2)(B)–(3)(B) unchanged ·
(vi) include provisions and procedures to permit multiple covered entities to jointly assert claims of overcharges by the same manufacturer for the same drug or drugs in one administrative proceeding, and permit such claims to be asserted on behalf of covered entities by associations or organizations representing the interests of such covered entities and of which the covered entities are members.
(C) Finality of administrative resolution The administrative resolution of a claim or claims under the regulations promulgated under subparagraph (A) shall be a final agency decision and shall be binding upon the parties involved, unless invalidated by an order of a court of competent jurisdiction.
(D) [inserted: Claims of violations.—] [inserted: Not later than 180 days after the date of the enactment of this subparagraph, the Secretary shall promulgate regulations to permit covered entities to assert claims of violations of subsections (a)(1) and (a)(11) under the process established under subparagraph (A).]
(4) Authorization of appropriations There are authorized to be appropriated to carry out this subsection, such sums as may be necessary for fiscal year 2010 and each succeeding fiscal year.
(e) Exclusion of orphan drugs for certain covered entities For covered entities described in subparagraph (M) (other than a children’s hospital described in subparagraph (M)), (N), or (O) of subsection (a)(4), the term “covered outpatient drug” shall not include a drug designated by the Secretary under section 360bb of title 21 for a rare disease or condition.